Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02064790 · ClinicalTrials.gov registry record
Comparison of Gabapentin and Pregabalin for Radicular Pain
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 6
- Enrollment target
NCT02064790 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 6 participants.
The verdict
NCT02064790 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
Study Summary
Although some studies show improvement of pain and associated effects of pain with off-label use of neuropathic agents for cervical or lumbar radiculopathy, there is limited published evidence so far. We propose to complete a year-long prospective, observational study as a pilot to recruit 400 patients within the year and follow their pain level, function, and QOL measures for 16 weeks to determine whether it is feasible to continue studying this group in the future. We expect that pain, function, and quality of life will be improved in the group of patients who are given neuropathic agents as an adjunct to other conservative treatments compared to the expected 65% of patients with similar symptoms who are treated conservatively without neuropathic agents. We do not expect a statistically significant difference between the two neuropathic agents. Since these drugs are currently used off-label, there is limited empirical evidence regarding which agent is more efficacious compared to the other, and since their use in treating radicular pain is based mostly on anecdotal evidence so far, prescription of one or the other of these agents has been based on likely compliance (medication needed twice a day, three times a day) or whether or not the patients' insurance will pay for one or the other. This study will be a first step to better assist practitioners in counselling their patients on use of these medications in radiculopathy, examining rates of discontinuation due to side effects and what effects these medications have on perceived pain, function and quality of life.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02064790
The ClinicalTrials.gov registry entry for NCT02064790 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02064790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02064790 about?
NCT02064790 is a clinical study titled "Comparison of Gabapentin and Pregabalin for Radicular Pain". Although some studies show improvement of pain and associated effects of pain with off-label use of neuropathic agents for cervical or lumbar radiculopathy, there is limited published evidence so far. We propose to complete a year-long prospective, observational study as a pilot to recruit 400 patie...
What is the current status of trial NCT02064790?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2014-04. Estimated completion is 2015-12.
Who is sponsoring clinical trial NCT02064790?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.